Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.
Saved in:
| Title: | Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials. |
|---|---|
| Authors: | Jansen, Ellen1 (AUTHOR), Bockstal, Viki1 (AUTHOR), Herschke, Florence1 (AUTHOR) fherschke@exevir.com, Olsson Gisleskog, Per2 (AUTHOR), Rinaldi, Manuela1 (AUTHOR), Boerboom, Angélique1 (AUTHOR), Hadi, Salah3 (AUTHOR), Gaibu, Natalia4 (AUTHOR), Moutschen, Michel5 (AUTHOR), Tersago, Dominique1 (AUTHOR) |
| Source: | PLoS Medicine. 5/29/2026, Vol. 23 Issue 5, p1-20. 20p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 15491277 |
|---|---|
| DOI: | 10.1371/journal.pmed.1004609 |
